About this project
Atopic dermatitis (AD) is a chronically relapsing, inflammatory skin disease, which affects 2-5% of the adult population and 10-20% of children worldwide.
Treatment of AD is symptomatic and is generally considered unsatisfactory with limited efficacy. This stems in large part from an incomplete understanding of the multifactorial pathogenesis of AD, involving environmental, genetic and immunologic factors. Therefore, although AD is commonly described as a single disease, its complexity suggests a need for better classification into specific disease subtypes (endotypes), each associated with distinct underlying molecular mechanisms and treatment responses. It is such an in-depth characterization, enabling a full molecular understanding of the endotypes of AD, which is the main aim of the current project. Thus, we expect to identify biomarkers of AD that will a) improve differential diagnosis of AD, b) increase our molecular understanding of AD pathogenesis, and c) accelerate development of novel, pathway-directed therapeutic approaches.
Specifically, we will employ an integrative, systems biology approach by extensive, cellular and molecular profiling of patient skin, blood and urine using cutting edge technologies, including genomics, next-generation sequencing, metabolomics, microbiome analysis, highly sensitive immunoassays and state of the art bioinformatics.
It will be the first investigation of its kind that incorporates cellular and molecular biomarkers of both lesional and non-lesional skin and of systemic inflammation as a function of time and place to fully characterize AD patients based on disease severity and phenotypes. Our ambition is to obtain a comprehensive understanding of the molecular features of the endotypes of AD. Such an understanding will pave the way for development of new and improved treatments.
The successful candidate will be in charge of managing, integrating, analyzing and reporting on the data generated in the project. Additional tasks include: participation in relevant PhD courses and dissemination of your research at meetings and international congresses.
- A completed masters degree in bioinformatics, computer science, statistics or another relevant area
- Experience with integrative methods for analysis of multi-dimensional data
- Strong statistical skills, including experience in the scripting language R
- Good knowledge of cellular and molecular biology
- Proficiency in English, both in writing and speech
It will be an advantage if you
- are self-motivated, have strong analytical skills, and a focused approach to problem solving
- thrive with high expectations, independence, and substantial responsibility
- have worked with transcriptomics data, such as RNA-seq
- have programming experience, e.g. in Python or R
- have excellent interpersonal skills
- love data
The position is available from Sep 1 or by appointment
Applications including a short CV should be sent to: Thomas Litman, TYLDK@leo-pharma.com
To learn more about the position, please contact: Thomas Litman, CEL +45 4185 1753
Location: LEO Pharma, Industriparken 55, 2750 Ballerup, Denmark.
Post expires on Sunday June 30th, 2019